SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$42.38 USD
-0.43 (-1.00%)
Updated May 24, 2024 04:00 PM ET
After-Market: $42.34 -0.04 (-0.09%) 7:48 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
SpringWorks Therapeutics [SWTX]
Reports for Purchase
Showing records 61 - 80 ( 188 total )
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Relevant Abstracts at Upcoming EORTC-NCI-AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Competitor KOL Event Pays Homage to Emperor Niro
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
First Ovarian Granulosa Cell Tumor Patient Dosed With Nirogacestat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat is New Standard-of-Care for Desmoid Tumors; RAFi Competitive Landscape Updates; Modulating PT to $103
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Niro Breaking the Competition in Desmoid Tumors
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
ESMO 2022 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Awaiting Clarity for Nirogacestat + BCMA-Targeted Agents; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Multiple 2H22 Data Releases; 2Q22 Financials; Modulating PT to $94
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Another Contender in the RING in the Desmoid Division
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D